MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands.

[1]  V. Arndt,et al.  Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. , 2017, Cancer epidemiology.

[2]  E. Roman,et al.  Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15 , 2016, Cancer epidemiology.

[3]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[4]  P. Sonneveld,et al.  Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry , 2015, Leukemia.

[5]  P. Sonneveld,et al.  The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. , 2015, Leukemia research.

[6]  M. Ballesteros,et al.  Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts , 2015, Annals of Hematology.

[7]  P. Sonneveld,et al.  Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. , 2014, European journal of cancer.

[8]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[9]  U. Germing,et al.  Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. , 2013, Leukemia research.

[10]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[11]  Z. Estrov,et al.  Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. , 2011, Blood.

[12]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[13]  N. Howlader,et al.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.

[14]  S. Mayne,et al.  Myelodysplastic syndromes , 2007, Cancer.

[15]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.